Results 171 to 180 of about 15,269 (294)

CD93—An emerging vascular target in cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira   +3 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

Perforin and Granulysin-Mediated Cytotoxicity in Colorectal Cancer Patients. [PDF]

open access: yesMedicina (Kaunas)
Letica L   +9 more
europepmc   +1 more source

Targeting the pyroptosis network: Research progress of natural products in intervention for acute lung injury

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Acute lung injury (ALI) is a serious clinical condition with high morbidity and mortality rates. Current ALI treatments have limitations. Natural products from traditional Chinese medicine (TCM) exhibit multi‐component, multi‐target and multi‐pathway regulatory properties with good safety, making them promising candidates for ALI treatment ...
Cheng Luo   +10 more
wiley   +1 more source

CAR T-Cell Therapy in Hematological Malignancies: Mechanisms, Innovations, and Challenges. [PDF]

open access: yesCancers (Basel)
Aljabali AAA   +11 more
europepmc   +1 more source

The Role of IGF2BP3‐Mediated Immune Response Activation in Enhancing Immunotherapy of Koumine for Gastric Cancer

open access: yesCancer Science, EarlyView.
Koumine binds IGF2BP3 and promotes its proteasomal degradation, reducing m6A on EED mRNA, accelerating EED decay, lowering H3K27me3, and promoting IRF transcription, thereby restoring MHC‐I and enhancing CD8+ T cell killing. ABSTRACT Resistance to immune checkpoint blockade in gastric cancer often arises from defective antigen presentation due to MHC‐I
Qiu Hongqiang   +10 more
wiley   +1 more source

The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy. [PDF]

open access: yesCancer Immunol Immunother
El-Sehrawy AAMA   +7 more
europepmc   +1 more source

Adding Intratumoral Antibody‐Photoabsorber Conjugate Improves Efficacy of Near‐Infrared Photoimmunotherapy (NIR‐PIT)

open access: yesCancer Science, EarlyView.
Intravenous (IV) or intratumoral (IT) cetuximab distribution in A431 tumor (essence of Figure 2). ABSTRACT Near‐infrared photoimmunotherapy (NIR‐PIT) is a new type of cancer treatment that specifically kills target cells while sparing normal tissue. This treatment induces cancer cell death by activating a photoreactive dye with near‐infrared light in ...
Miyu Kano   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy